. 2019 Oct 24;4(1):141–153. doi: 10.1002/rth2.12261

Table 2.

Non‐persistent patients on DOAC and those who switched from their initial DOAC to another anticoagulant

Follow‐up	Pt. at risk	Non‐persistent patients	Incidence of non‐persistence^a (%)	Cumulative incidence^a (%)	Pt. who switched initial DOAC				Percentage
Follow‐up	Pt. at risk	Non‐persistent patients	Incidence of non‐persistence^a (%)	Cumulative incidence^a (%)	Pt. at risk	To any anticoagulant	Percentage	To VKA	Percentage
Any DOAC
≤6 wk	77 333	5781	8	8	5912	266	5	241	91
6 wk‐6 mo	70 100	13 963	19	27	14 661	1139	8	726	64
6‐mo‐1 y	44 569	3494	7	34	4439	1356	31	875	65
1‐2 y	23 239	3150	9	43	5058	2543	50	1639	65
2‐3 y	13 005	1372	8	51	2622	1657	63	1101	66
3‐4 y	5301	593	13	64	1931	1572	81	1123	71
Total		28 353	64		34 623	8533	25	5705	67

Abbreviations: DOAC, direct oral anticoagulant; Pt, patients, VKA, vitamin K antagonist.

Estimated by cumulative incidence as determined from survival tables in Kaplan Meier analyses.